Moleculin Biotech
MBRX
17 hedge funds and large institutions have $1.85M invested in Moleculin Biotech in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
30% more capital invested
Capital invested by funds: $1.42M → $1.85M (+$428K)
21% more funds holding
Funds holding: 14 → 17 (+3)
0.37% more ownership
Funds ownership: 3.62% → 3.99% (+0.37%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIC
Whitegate Investment Counselors
Concord,
New Hampshire
|
+$186K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$169K |
| 3 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$125K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$26K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$21.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$21K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.65K |
| 3 |
Morgan Stanley
New York
|
-$4.33K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4K |
MBRX Hedge Fund Activity: Q1 2018 in Review
17 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2018, worth a combined $1.85M — up 30% from $1.42M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MBRX positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Whitegate Investment Counselors, opening a new position worth an estimated $186K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $21K sold.
- 17 institutional investors held Moleculin Biotech (MBRX) as of Q1 2018, up from 14 in Q4 2017.
- Funds reported $1.85M of Moleculin Biotech stock for Q1 2018, up 30% quarter-over-quarter.
- 6 funds opened new Moleculin Biotech positions in Q1 2018 and 3 closed out, a net change of +3 holders.
- The largest Moleculin Biotech buyer in Q1 2018 was Whitegate Investment Counselors, an estimated $186K added.
- The largest Moleculin Biotech seller in Q1 2018 was Two Sigma Securities, an estimated $21K sold.
Based on aggregated 13F filings for Q1 2018.